Compare XMTR & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | LGND |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2021 | N/A |
| Metric | XMTR | LGND |
|---|---|---|
| Price | $92.59 | $271.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $58.60 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 778.3K | 175.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | $1.25 |
| Revenue Next Year | $18.38 | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $30.63 | $111.72 |
| 52 Week High | $99.86 | $267.27 |
| Indicator | XMTR | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 79.93 |
| Support Level | $56.76 | $199.97 |
| Resistance Level | $99.86 | N/A |
| Average True Range (ATR) | 4.54 | 7.64 |
| MACD | -0.68 | 2.94 |
| Stochastic Oscillator | 70.88 | 99.67 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.